Gail L. Wrigley
AstraZeneca (United Kingdom)(GB)The Francis Crick Institute(GB)Research & Development Establishment (Engrs.)(IN)AstraZeneca (Netherlands)(NL)AstraZeneca (Singapore)(SG)AstraZeneca (Brazil)(BR)AstraZeneca (Poland)(PL)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, HER2/EGFR in Cancer Research, Chemical Synthesis and Analysis
Most-Cited Works
- → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
- → Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs(2020)221 cited
- → Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation(2015)118 cited
- → Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)(2016)85 cited
- → The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor(2019)77 cited